Welcome to our dedicated page for 2Seventy Bio SEC filings (Ticker: TSVT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Every 10-K from 2seventy bio reads like a clinical dossier—CAR-T response rates, royalty waterfalls, and cash-runway projections buried in dense scientific language. If you are combing an 8-K for unexpected FDA feedback or chasing “2seventy bio insider trading Form 4 transactions” before the next oncology conference, navigating hundreds of pages can drain precious hours.
Stock Titan fixes that problem. Our AI-powered analysis decodes each filing the moment it hits EDGAR, delivering clear, plain-English takeaways. Need the “2seventy bio quarterly earnings report 10-Q filing” summarized? We spotlight pipeline spend versus guidance and liquidity ratios. Want alerts on “2seventy bio Form 4 insider transactions real-time” or “2seventy bio executive stock transactions Form 4”? You’ll know the instant an officer buys or sells. From “2seventy bio annual report 10-K simplified” to “2seventy bio proxy statement executive compensation,” it’s truly “2seventy bio SEC filings explained simply.” Ask any AI assistant about “understanding 2seventy bio SEC documents with AI” or “2seventy bio earnings report filing analysis,” and they’ll point you here.
Why do investors zero in on these disclosures? Pipeline milestones, Worcester manufacturing scale-ups, and partnership economics move the stock long before revenue does. Our coverage connects the dots:
- 10-K / 10-Q – cash burn, clinical trial timelines, segment revenue, all with AI commentary.
- Form 4 insider transactions real-time – track “2seventy bio executive stock transactions Form 4” ahead of material events.
- 8-K material events explained – instant clarity on study readouts, collaboration deals, or leadership changes.
Save time, gain insight, and act with confidence—Stock Titan keeps every 2seventy bio filing current, searchable, and understandable.
Glazer Capital, LLC and Paul J. Glazer filed a Schedule 13G/A regarding 2seventy bio's common stock. The filing discloses that neither Glazer Capital nor Mr. Glazer beneficially own any shares of the company's common stock, reporting 0 shares (0.00%) and no sole or shared voting or dispositive power. The statement classifies Glazer Capital as an investment adviser/other and Mr. Glazer as an individual reporting person, and includes a certification that the securities were not acquired to influence control of the issuer. This filing is a routine ownership disclosure rather than an acquisition or control notice.
The reporting persons — Beryl Capital Management LLC, Beryl Capital Management LP, Beryl Capital Partners II LP and David A. Witkin — submitted a Schedule 13G/A with respect to 2seventy bio, Inc.'s common stock. Each reporting person disclaims beneficial ownership except to the extent of any pecuniary interest and reports zero shares and 0% ownership. The cover information lists reporting-person classifications including IA, OO, PN, HC, and IN.
The filing contains certifications that the securities were acquired and are held in the ordinary course of business and were not acquired to influence control. The submission states no sole or shared voting or dispositive power for any reporting person and attaches Exhibit 99.1 (agreement regarding joint filing).
2seventy bio, Inc. Schedule 13G/A shows The Goldman Sachs Group, Inc. and Goldman Sachs & Co. LLC jointly report beneficial ownership of 308 shares of the issuer's common stock. The filers state no sole voting or dispositive power and report shared voting power of 133 shares and shared dispositive power of 308 shares. The reported amount represents 0.0% of the class and is described as ownership of 5% or less. The filers certify the securities are held in the ordinary course of business and not for the purpose of changing control. The filing includes a joint filing agreement and identifies GS Group as a parent holding company with Goldman Sachs as a subsidiary broker-dealer and investment adviser.
FAQ
What is the current stock price of 2Seventy Bio (TSVT)?
What is the market cap of 2Seventy Bio (TSVT)?
